Serum calretinin as a biomarker in malignant mesothelioma

Zupanc, Cita (avtor), Franko, Alenka (avtor), Štrbac, Danijela (avtor), Dodič-Fikfak, Metoda (avtor), Kovač, Viljem (avtor), Dolžan, Vita (avtor), Goričar, Katja (avtor)

The early diagnosis of malignant mesothelioma (MM) could improve the prognosis of MM patients. To confirm an MM diagnosis, an immunohistochemical analysis of several tumor tissue markers, including calretinin, is currently required. Our aim is to evaluate serum calretinin as a potential biomarker in asbestos-related diseases, especially in MM. Our study includes 549 subjects: 164 MM patients, 117 subjects with asbestosis, 195 subjects with pleural plaques and 73 occupationally asbestos-exposed subjects without asbestos-related diseases. The serum calretinin concentration was determined with a commercially available enzyme immunoassay. Data on the soluble mesothelinrelated peptides (SMRP) concentration are available from previous studies. MM patients had a significantly higher calretinin concentration than subjects without disease, subjects with pleural plaques or subjects with asbestosis (all p < 0.001). The histological type was significantly associated with serum calretinin: patients with sarcomatoid MM had lower calretinin than patients with the epithelioid type (p = 0.001). In a ROC curve analysis, the area under the curve for calretinin concentration predicting MM was 0.826 (95% CI = 0.782–0.869; p < 0.001). At the cutoff value of 0.32 ng/mL, sensitivity was 0.683, while specificity was 0.886. The combination of calretinin and SMRP had the highest predictive value. Calretinin is a useful biomarker that can distinguish MM from other asbestos-related diseases and could, therefore, contribute to an earlier non-invasive diagnosis of MM.

• Jezik: Angleški jezik
• Ključne besede: malignant mesothelioma, calretinin, asbestos-related disease, biomarker
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2021
• Št. strani: 11 str.
• Številčenje: Vol. 10, iss. 21, art. 4875
• PID: 20.500.12556/RUL-136448
• UDK: 616-057
• ISSN pri članku: 2077-0383
• DOI: 10.3390/jcm10214875
• COBISS.SI-ID: 83032579
• Datum objave v RUL: 04.05.2022

Gradivo je del revije

• Naslov: Journal of clinical medicine
• Skrajšan naslov: J. clin. med.
• Založnik: MDPI
• ISSN: 2077-0383
• COBISS.SI-ID: 5405759

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 01.11.2021

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: maligni mezoteliom, kalretinin, bolezen, povezana z azbestom